Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

August 1, 2019August 2, 2019

Adempas May Improve Endothelial Cells’ Function in CTEPH, Study Suggests

CTEPH News, News

The vasodilator Adempas (riociguat) increases the ability of endothelial progenitor cells to halt vascular remodeling and enhance formation of new blood vessels in chronic thromboembolic pulmonary hypertension (CTEPH), according to a new ... Read more

July 17, 2019July 17, 2019

Raising Levels of Nur77 May Help Halt Progression of PH, Study Suggests

News, PAH News, PH News

Increasing levels of the receptor Nur77 in cells lining the blood vessels of patients with pulmonary hypertension (PH) may help halt progression of the disease by enhancing the signaling ... Read more

July 10, 2019July 10, 2019

TAVI Heart Valve Surgery Has Fewer Complications for PH Patients, Analysis Shows

News

In patients with pulmonary hypertension (PH) with aortic stenosis — when the heart’s aortic valve fails to properly close/open — undergoing a transcatheter aortic valve implantation (TAVI) surgical procedure ... Read more

June 17, 2019June 17, 2019

Opsumit Shows Promise for Portopulmonary Hypertension in Phase 4 Trial

News, PAH News

Treatment for 12 weeks with Actelion Pharmaceuticals’ Opsumit (macitentan) significantly improved blood vessels’ resistance in patients with portopulmonary hypertension without causing further damage to the liver, data from the PORTICO ... Read more

June 6, 2019June 6, 2019

AIT Therapeutics Secures $8M to Further its Nitric Oxide Delivery System for Respiratory Conditions

News, PH News

AIT Therapeutics has obtained a funding agreement that will raise $8 million through private investment in public equity (PIPE) financing to further development of its nitric oxide-based treatments for persistent pulmonary ... Read more

June 3, 2019June 3, 2019

AIT Therapeutics’ New Nitric Oxide Ventilator Safer for Patients and Healthcare Staff, Study Shows

News

AIT Therapeutics’ on-demand nitric oxide (NO) ventilator is safer for patients with pulmonary hypertension (PH), and for healthcare workers, compared with standard NO cylinders, a study shows. The study’s ... Read more

May 29, 2019May 29, 2019

Bayer US Launches $1 Million Grant Program to Boost Clinical Research into PH

CTEPH News, News, PAH News, PH News

The Pulmonary Hypertension Accelerated Bayer (PHAB) Awards, recently launched by Bayer US, will grant up to $1 million dollars for clinical research into pulmonary hypertension (PH). Spread over two years, ... Read more

May 13, 2019June 3, 2019

Balloon Pulmonary Angioplasty Can Improve Survival of Patients with Inoperable CTEPH, Study Suggests

News

Survival rates of patients with chronic thromboembolic pulmonary hypertension (CTEPH) unable to undergo surgical treatment have significantly improved in recent years, a retrospective study has found. This suggests that ... Read more

April 29, 2019April 30, 2019

Poor Heart Function Raises Risk of Early Death After Lung Transplant for IPAH Patients, Study Suggests

News, PAH News

Certain parameters of poor heart function are risk factors for early death among idiopathic pulmonary arterial hypertension (IPAH) patients who undergo lung transplant, a small Chinese study suggests. The ... Read more

April 24, 2019April 24, 2019

NT-proBNP Levels Can Predict Long-term Outcomes and Treatment Response in PAH Patients, Study Says

News, PAH News

Levels of NT-proBNP can predict long-term outcomes and response to treatment with Uptravi (selexipag) in patients with pulmonary arterial hypertension (PAH), a post-hoc analysis of the Phase 3 GRIPHON trial shows. ... Read more

Pin It on Pinterest